In this study, we have demonstrated for the first time that SIRT3 is moderately down-regulated in prostate cancers and patients with high SIRT3 copy number exhibit a significantly longer overall survival compared to those with low SIRT3 copy number. This evidence concerns the gene SIRT3 and prostate carcinoma.